THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

MS drug's predicted sales are lowered

By Jeffrey Krasner
Globe Staff / August 30, 2005

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

Even if Biogen Idec Inc. is able to win regulatory approval to sell its multiple sclerosis drug Tysabri, sales probably will not be enough to have a significant impact on the Cambridge company, according to a report by a Wall Street analyst. (Full article: 517 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly